Study of belumosudil for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or not responded to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeted antibody.
- You are 18 years or older.
- You have measurable signs of myeloma, like a certain level of M-protein in blood or urine, or enough plasma cells in your bone marrow.
- Your kidney, liver, heart, and blood cell counts are good enough to safely receive the study drug.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.